Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 6Lymphoma, Non-Hodgkin 5Lymphoma 5Waldenstrom Macroglobulinemia 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Large-Cell, Immunoblastic 2Burkitt Lymphoma 2

Interventions

Rituximab 16Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 11fludarabine phosphate 10Cytarabine 9Methotrexate 8Vincristine 7blinatumomab 6Filgrastim 6Etoposide 6fludarabine 5Prednisone 5Mycophenolic Acid 5Lenalidomide 5Dexamethasone 5Cyclosporine 5merphos 4Whole-Body Irradiation 4Radiotherapy 4Ifosfamide 4Carboplatin 4venetoclax 3romidepsin 3prednylidene 3deltacortene 3Spinal Puncture 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Inotuzumab Ozogamicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Burkitt Lymphoma × ibritumomab tiuxetan × Clear all
NCT00031642 2023-12-27

Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation

University of Nebraska

Phase 1/2 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00064246 2013-01-25

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

National Cancer Institute (NCI)

Phase 1/2 Completed
28 enrolled
Lymphoid

Burkitt Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡